BioMedical Materials (BMM) Consortium
Research Areas
At a Glance
- Status: Completed Consortium
- Year Launched: 2007
- Initiating Organization: Government of the Netherlands
- Initiator Type: Government
- No disease focus
- Location: Europe
Abstract
The BioMedical Materials (BMM) consortium focuses on advancing the use of new materials to biomedical research. As a public-private partnership, the consortium includes the participation of over 50 leading institutions, corporations, and health foundations, with support from the government of the Netherlands.
Mission
The BioMedical Materials (BMM) consortium aims to develop new materials for biomedical applications. Established in 2007 as a pre-competitive partnership, BMM has brought together over 50 partners from the private and public sectors to develop new therapies and products to combat organ and tissue failure. The current portfolio includes 18 pre-clinical projects in research domains at the interface of a variety of prevalent diseases and technologies, to advance the creation of therapies and other medical products.
Structure & Governance
The BMM Executive Board is responsible for the day-to-day management of BMM, for its financials, for building and expanding the BMM partnership, for the monitoring of the progress of the various BMM projects, and for the support by the BMM office in Geleen.
The BMM Supervisory Board provides oversight to the consortium’s project portfolio, following the advice of the BMM International Scientific Advisory Board, and the approval of the Annual Financial Accounts of BMM. The BMM Supervisory Board also appoints the members of the BMM Executive Board. The members of the BMM Supervisory Board are selected form the group of BMM partners.
Representatives of all BMM partners meet annually in the General Assembly of BMM partners. In this meeting the partners are informed about the progress of the BMM projects and activities and jointly they discuss the options for the future of the BMM partnership. The meeting is usually organized co-incidentally with the scientific BMM Annual Meeting.
The International Scientific Advisory Board (ISAB) ensures the scientific integrity and provides oversight to the BMM projects. The ISAB reports to the Supervisory Board for the approval of project proposals and annually on the progress and continuation of the projects. The ISAB comprises of 7 international specialists in the technological and disease areas of BMM.
Financing
The consortium operates with a € 90 M budget, provided by the government of the Netherlands
Impact / Accomplishment
The BMM Valorization Grant has led to the start of the first spin-off company based on the outcome of a BMM project. Additional accomplishments are provided in the consortium’s annual report.
|
Homepage |
Points of Contact
BioMedical Materials
Urmonderbaan 20/A
NL-6167 RD GELEEN
NETHERLANDS
T +31 (46) 702 2280
E info@bmm-program.nl
Sponsors & Partners
|
Academic Medical Center |
|
Erasmus MC |
|
Leiden University Medical Center |
|
Maastricht UMC+ |
|
University of Groningen |
|
TUDelft |
|
Technische Universiteit Eindhoven |
|
UMCG |
|
University Medical Center Utrecht |
|
Radboud University Medical Center |
|
Universiteit Leiden The Netherlands |
|
Universiteit Utrecht |
|
Penn Medicine |
|
University of Twente |
|
Universitat Zurich |
|
VUmc |
|
AXLE International |
|
BAAT Medical Engineering |
|
Bio Comp |
|
Biocompatibles |
|
Biomet |
|
Cam Bioceramics |
|
CellCoTec |
|
Dolphys |
|
DSM |
|
European Medical Contract Manufacturing |
|
FeyeCon |
|
Fortimedix |
|
Ft. Innovations B.V. |
|
Fujifilm |
|
Genus Biotech |
|
Hartstichting |
|
InGell |
|
Innocore Pharmaceuticals |
|
MagnaMedics |
|
Nanomi Monosphere Technology |
|
Nierstichting |
|
NT-MDT |
|
PCI Biotech |
|
Percuros |
|
PharmaCell |
|
Philips |
|
Reumafonds Dutch Arthritis Foundation |
|
SolMates |
|
SupraPolix |
|
SyMO-Chem |
|
TNO Innovation for Life |
|
Xeltis |
|
Xpand Biotechnology |
|
ZF Screens. |